Exploiting cell death and tumor immunity in cancer therapy: challenges and future directions

Abstract

Cancer remains a significant global challenge, with escalating incidence rates and a substantial burden on healthcare systems worldwide. Herein, we present an in-depth exploration of the intricate interplay between cancer cell death pathways and tumor immunity within the tumor microenvironment (TME). We begin by elucidating the epidemiological landscape of cancer, highlighting its pervasive impact on premature mortality and the pronounced burden in regions such as Asia and Africa. Our analysis centers on the pivotal concept of immunogenic cell death (ICD), whereby cancer cells succumbing to specific stimuli undergo a transformation that elicits robust anti-tumor immune responses. We scrutinize the mechanisms underpinning ICD induction, emphasizing the release of damage-associated molecular patterns (DAMPs) and tumor-associated antigens (TAAs) as key triggers for dendritic cell (DC) activation and subsequent T cell priming. Moreover, we explore the contributions of non-apoptotic RCD pathways, including necroptosis, ferroptosis, and pyroptosis, to tumor immunity within the TME. Emerging evidence suggests that these alternative cell death modalities possess immunogenic properties and can synergize with conventional treatments to bolster anti-tumor immune responses. Furthermore, we discuss the therapeutic implications of targeting the TME for cancer treatment, highlighting strategies to harness immunogenic cell death and manipulate non-apoptotic cell death pathways for therapeutic benefit. By elucidating the intricate crosstalk between cancer cell death and immune modulation within the TME, this review aims to pave the way for the development of novel cancer therapies that exploit the interplay between cell death mechanisms and tumor immunity and overcome Challenges in the Development and implementation of Novel Therapies.

1 Background

Cancer is a major global health concern, responsible for millions of deaths annually. The International Agency for Research on Cancer (IARC) reports that cancer is the foremost or second-leading cause of death before the age of 70 in 112 out of 183 surveyed countries (Bray et al., 2021). Cancer cells possess unique characteristics enabling them to evade cell death and the immune system, making inducing cancer cell death an crucial aspect of therapy (Chi et al., 2022a; Zhao S. et al., 2022; Chi et al., 2022b).

The Nomenclature Committee on Cell Death (NCCD) has categorized cell death into accidental (ACD) and regulated (RCD) forms (Hanahan and Weinberg, 2011). RCD, orchestrated by specific molecular mechanisms, includes apoptotic and non-apoptotic variants such as ferroptosis, autophagy, pyroptosis, and necroptosis (Gao et al., 2022). Targeting non-apoptotic RCD pathways with drugs could overcome apoptosis resistance and impact cancer treatment (Muppa et al., 2019; Koren and Fuchs, 2021). Necroptosis, ferroptosis, and pyroptosis interact with tumor immunity in the TME, known as immunogenic cell death (ICD) (Tang R. et al., 2020; Shen et al., 2022; Song et al., 2022).

ICD in the TME activates anti-tumor immune responses, involving dendritic cells (DCs) presenting antigens to T cells, leading to cancer cell elimination and anti-tumor immunity development (Xie et al., 2017). Inducing necroptosis, ferroptosis, or pyroptosis in tumor cells can enhance anti-tumor immune responses and reduce tumor growth and metastasis (Xie et al., 2017; Tang R. et al., 2020; Chen et al., 2021a). This review explores the roles of both ICD (Immunogenic Cell Death) and non-apoptotic RCD (Regulated Cell Death) in the modulation of tumor immunity within the tumor microenvironment (TME). It proposes the TME as a viable target for innovative cancer therapies. Additionally, the aim is to provide readers with an understanding of the various forms of cell death induced by different therapies and their impact on anti-tumor immune responses. The review strives to examine the potential therapeutic approaches for enhancing and developing anti-tumor immunity through the utilization of these cell death mechanisms. Furthermore, it discusses the challenges associated with tumor resistance to cell death induction, the complexity of the tumor microenvironment, and the possible incorporation of new technologies to tackle these obstacles.

2 Immunogenic cell death, inflammation-associated pyroptosis, necroptosis, and ferroptosis

2.1 immunogenic cell death

ICD is a type of cancer cell demise triggered by certain treatments such as chemotherapeutic agents, oncolytic viruses, therapies, and radiotherapy (Ahmed and Tait, 2020). The non-immunogenic characteristics of tumor cells can transform into immunogenic traits upon exposure to these stimuli, leading to the production of anti-tumor immune responses (Galluzzi et al., 2020). ICD can be induced by intracellular pathogens, different types of drugs, and various physical therapies (Galluzzi et al., 2020). After ICD, cells release molecules known as DAMPs, TAAs, and pro-inflammatory cytokines. These molecules are captured by DCs and macrophages, processed, and presented to immune cells, ultimately resulting in antigen-specific immune responses (Duan et al., 2019). Pattern recognition receptors (PRRs) like Toll-like receptors (TLRs) and nucleotide-binding oligomerization domain-like receptors (NLRs) identify these molecules, stimulating tumor-specific immune responses. This process enhances the efficacy of anti-cancer medications by directly eliminating cancer cells and promoting anti-tumor immunity, including immune memory (Kroemer et al., 2022). Although pyroptosis, necroptosis, and ferroptosis can be considered forms of immunogenic cell death to some extent, they differ in their specific mechanisms and effects on immune system activation (Figure 1).

FIGURE 1

2.2 Inflammation-associated pyroptosis, necroptosis, and ferroptosis

Inflammation-associated pyroptosis is a form of cell death triggered by inflammasomes. It is characterized by cell swelling, rupture, and release of cellular contents (Hsu et al., 2021). Apoptotic caspases, including CASP1, CASP4, CASP5, CASP11, and murine CASP3, can also activate pyroptosis (Lee et al., 2023). NLRP3 inflammasomes are formed and caspase-1 is activated when pathogen-associated molecular patterns (PAMPs) and DAMPs bind to pattern recognition receptors. Caspase-1 cleaves gasdermin D (GSDMD), generating the N-terminal pore-forming domain (PFD) (Hou et al., 2020). The cleaved PFD of gasdermin induces oligomerization in the plasma membrane, resulting in cell death. It also promotes the maturation and release of active IL-1β and IL-18 (Holler et al., 2000; Tong et al., 2022). Lipopolysaccharide can directly activate CASP4, CASP5, and CASP11 to causes the above mechanism.

Necroptosis is another form of regulated cell death triggered by various factors, such as tumor necrosis factor (TNF), lipopolysaccharide (LPS), and nuclear DNA damage (Degterev et al., 2005; Galluzzi et al., 2017). Necroptosis shows morphological characteristics similar to necrosis, including organelle swelling, cell membrane rupture, and cytoplasmic and nuclear disintegration (Weinlich et al., 2017). Unlike apoptosis, necroptosis is caspase-independent. Under caspase-8 inhibition, receptor-interacting protein kinase 1 (RIPK1), RIPK3, and cylindromatosis (CYLD) remain active. The cellular death pathway can transition from apoptosis to necroptosis, leading to decreased cellular Adenosine triphosphate (ATP) levels (Temkin et al., 2006; Gong et al., 2019). Upon factors binding to cell membrane receptors, RIPK1 undergoes autophosphorylation and forms functional amyloid-like proteins, aided by Caspase-8 inhibition or E3 ligase family inhibitors. RIPK1 then interacts with RIPK3 to form the necrosome, initiating necroptosis. Phosphorylated mixed-lineage kinase domain-like (MLKL) translocates to the plasma membrane, forming an ion channel that increases membrane permeability and eventually leads to membrane rupture and DAMPs release, triggering necroptosis (Kaczmarek et al., 2013; Seo et al., 2021).

Ferroptosis is a non-apoptotic form of cell death characterized by the accumulation of lipid peroxidation (Dixon et al., 2012). It is dependent on iron and exhibits morphological changes, such as increased membrane density, mitochondrial shrinkage, reduced mitochondrial cristae, and normal nuclear morphology without chromatin condensation (Stockwell et al., 2017). Ferroptosis can be induced by various factors. Glutathione peroxidase 4 (GPX4) inhibits the generation of active lipid oxygen, but when the cystine-glutamate transporter (system xc-) is inhibited, the uptake of glutathione (GSH) decreases, leading to decreased GPX4 activity and initiation of ferroptosis (Yang et al., 2014). p53 can also trigger ferroptosis by downregulating the expression of SLC3A2, decreasing GSH synthesis and GPX4 activity (Chu et al., 2019). RSL3, DPI10, and mevalonate pathway-targeting molecules directly influence GPX4 and induce ferroptosis (Yu et al., 2017; Chen et al., 2021b). When iron is present, the peroxidation of polyunsaturated fatty acids (PUFAs) in cellular membrane lipids generates reactive oxygen species that oxidize adjacent PUFAs, resulting in membrane phospholipid peroxidation and ferroptosis (Lee et al., 2021). Components of the autophagy machinery, such as ATG3 and ATG5, can also activate ferroptosis (Zhou et al., 2020). Although the immunogenicity of ferroptosis is not extensively studied, preliminary evidence suggests that it may trigger immune responses by releasing DAMPs (Wen et al., 2019; Tang D. et al., 2020).

3 Immunity and tumor cell death

Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy, but many tumors do not respond well, it is often due to low levels of tumor-infiltrating lymphocytes (TIL). This limitation hinders the broader use of ICIs in immunotherapy (Chi et al., 2022b). TILs reside in the TME, which surrounds tumor cells and significantly impacts tumor progression through various secreted factors. The TME includes stromal cells, immune cell populations (T and B lymphocytes, neutrophils, TAMs et al.), among others (Junttila and de Sauvage, 2013). Modulating the TME and TIL composition by inducing immunogenic cell death (e.g., necroptosis, ferroptosis, or pyroptosis) shows promise in enhancing anti-tumor immunity (Niu et al., 2022).

3.1 Immunogenic cell death

During immunogenic cell death in cancer cells, various substances enhance the immune response and kill more tumor cells (Xie et al., 2022). High mobility group box 1 protein (HMGB1), alone or in combination with Toll-like receptors and receptor for advanced glycosylation end-products (RAGE), promotes inflammatory reactions (Although it mainly exists in the serum of arthritis patients and at the inflammatory sites of patients with septicemia, some studies suggest that it may also be a therapeutic target for cancer patients.), produces pro-inflammatory cytokines, and enhances antigen presentation by DCs, resulting in powerful anti-tumor immune effects (Lotze and DeMarco, 2003; van Beijnum et al., 2008). Calreticulin (CRT) engagement with CD91 fosters the maturation and activation of DCs, culminating in the cross-presentation of tumor antigens and the elicitation of tumor-specific cytotoxic T lymphocyte (CTL) responses. This progression concurrently stimulates the secretion of pro-inflammatory cytokines such as TNF-α and IL-6, bolstering the anti-tumor immune response through diverse mechanisms (but total or membrane-exposed CALR levels are closely associated with prognosis in different cancer types, such as patients with myeloproliferative neoplasms carrying CALR mutations showing better outcomes compared to patients with wild-type CALR.) (Pawaria and Binder, 2011; Fucikova et al., 2021). The binding of ATP to its receptor also triggers the activation of cytotoxic T lymphocytes (CTLs), propels DC activation and maturation, and expands macrophage populations (Elliott et al., 2009; Troitskaya et al., 2022).

3.2 Inflammation-related pyroptosis

In the immune defense mechanism, pyroptosis occurs more frequently than necroptosis and ferroptosis (Hsu et al., 2021). Gasdermin (GSDM) proteins act as key executors of pyroptosis, directly inducing cancer cell lysis and the release of immune-stimulating cellular contents. Additionally, they aggregate and activate immune cells such as CD4 andCD8 T cells, thus promoting tumor cell death (CT26 colorectal carcinoma and B16 melanoma in mouse) (Kong and Zhang, 2023). Pyroptosis transforms the immunosuppressive “cold” TME into an immunogenic “hot” TME, facilitating the infiltration of tumor-infiltrating lymphocytes (Zhu and Li, 2023). A recent study demonstrated that delivering metal ions and immune adjuvant R848 together to the tumor tissue can enhance anti-tumor immunity through pyroptosis regulation (Feng et al., 2023). NLRP3 inflammasome activation can also promote intestinal epithelial cells to secrete IL-18, exerting an anti-tumor effect on immune cells such as CD4⁺ T cells (in AOM-induced colorectal cancer) (Du et al., 2016).

3.3 Necroptosis

Currently, there are two ways to induce anti-tumor immunity through necroptosis: using necroptotic tumor cells or fibroblast vaccines (Tang R. et al., 2020). Aes et al. (2016) demonstrated that necroptotic cells release DAMPs, which activate DCs, promote antigen presentation, and stimulate cytotoxic CD8⁺ T lymphocytes (Aaes et al., 2016). However, recent research has highlighted the crucial roles of BATF3+ cDC1 cells and CD8⁺ leukocytes in tumor control mediated by necroptotic cells (Snyder et al., 2019). Transplanting necrotic cells into the TME can activate BATF3+ cDC1 cells and CD8⁺ leukocytes via necroptosis, leading to a powerful immune response independent of DAMPs released by MLKL. In this process, NF-κB activation in dying cells is essential for initiating immune responses and facilitating interactions between necroptosis and the TME (.F10-OVA melanoma flank tumors and Lewis Lung (LL/2)-OVA adenocarcinoma flank tumors) (Snyder et al., 2019). Furthermore, RIPK3 activation in cancer cells can also induce TRIM3 to modulate and enhance the anti-tumor microenvironment (Park et al., 2021).

4 TME as a therapeutic target for cancer treatment

4.1 Immuno-stimulated cell death

4.1.1 Combined therapy targeting immuno-stimulated cell death

The TME is a potential target for cancer treatment by inducing ICD in tumor cells. Immune Checkpoint Blockade (ICB) therapy activates the immune system to target cancer cells by inhibiting immune checkpoint molecules on tumor cell surfaces (Xie et al., 2022). However, the Immune-Suppressive Tumor Microenvironment (ITM) can limit the effectiveness of ICB therapy. Combining ICB therapy with chemotherapy or Photothermal Therapy (PTT) and Photodynamic Therapy (PDT) enhances intratumoral cytotoxic T lymphocyte (CTL) infiltration and overcomes ITM constraints. ICG-mediated PTT facilitates the uniform distribution of nanoparticles (NPs) in tumor tissues, enhancing drug efficacy (Li et al., 2017). PDT directly damages tumor DNA and induces tumor cell autophagy, showing synergistic effects with targeted drugs (Robertson et al., 2009; Zhang et al., 2016; Wen et al., 2017; Wang et al., 2018). Additionally, PDT-assisted treatments reduce tumor cell oxygen consumption and block electron transfer chains (Zhao et al., 2020) (Figure 1). Chemotherapy or PDT induce tumor cell apoptosis, release antigens, and activate the immune system, promoting CTL activity. This combined therapy improves treatment efficacy and reduces side effects. Furthermore, nanodrug delivery systems targeting ITM, like NPs, enhance the effectiveness of ICB therapy. Loading immune checkpoint inhibitors into nanocarriers improves their bioavailability in tumor tissues, overcoming limitations of the multiple types of tumor microenvironment. These strategies offer promising avenues for cancer treatment.

4.1.2 The sword of radiation therapy–reactive oxygen species (ROS) system

ROS can also affect immune checkpoint molecule expression, such as PD-L1, in immune cells (Glorieux et al., 2021; He et al., 2024). Additionally, ROS can regulate T cell function and apoptosis, impacting immune checkpoint expression and immune cell activity (colorectal cancer) (Kesarwani et al., 2013).

In summary, ROS induced by RT can promote tumor cell death through multiple mechanisms and modulate immune cell function. They can also alter the tumor microenvironment and induce immunogenic tumor cell death.

4.1.3 Peptides immunoactivation of the tumor microenvironment

Therapeutic peptides are potent agents for eliminating bacteria and tumor cells, impacting immune system activity. They play a significant role in immune modulation by circumventing limitations of conventional treatments. LTX-315 is a novel therapeutic peptide known for inducing ICD. Zhou et al. (2016) used several types of fibrosarcomas on mice and they found It induces structural and functional changes in mitochondria, leading to cell death and the release of DAMPs. ACPP, another pro-apoptotic peptide, enhances macrophage phagocytic activity and promotes anti-tumor immune responses by disrupting the CD47-SIRPα interaction according to a study in mouse colon cancer cells (Koh et al., 2017; Wang et al., 2021). Peptides targeting various cells and signaling pathways within the TME are being investigated to boost immune activity against tumors (Table 1). Continued research on these peptides offers promising avenues for cancer treatment (Hayes et al., 2020; Aria and Rezaei, 2023).

4.2 Role of inflammation-associated cell pyroptosis and necroptosis in enhancing tumor immunogenicity

Pyroptosis and necroptosis are programmed cell death mechanisms that hold potential in cancer therapy by enhancing tumor immunogenicity and immune cell infiltration in the TME. Pyroptosis, triggered by gastrin-releasing peptide, can transform “cold tumors” into “hot tumors” by augmenting the immune response (Zhang R. N. et al., 2023). Colorectal cancer (CRC) treated with gambogic acid (GA) amplifies the ratio of immune cells such as CD3 T cells, cytotoxic T lymphocytes, dendritic cells, and effector memory T cells, promoting Pyroptosis and enabling chemotherapy drugs to modulate the TME and improve antitumor efficacy (Xu et al., 2022).

Various drugs, including metformin, anthocyanins, and dehydroacetic acid, are capable of inducing Pyroptosis and potentiating anticancer immunity (on human hepatocellular carcinoma,naïve breast cancer and et al.) (Paixão et al., 2017; Kheirandish et al., 2018; Zhou et al., 2018). However, cancer cells can evade Pyroptosis through immune suppression pathways and drug resistance mechanisms. To address this issue, Feng et al. developed an acid-responsive Fe/Mn bimetallic organic framework nanosystem loaded with metal ions and an immune adjuvant R848 (FeMn@R@H). This nanosystem initiates ROS-mediated Pyroptosis via Fenton-like reaction, reverses the suppressive tumor immune microenvironment, and amplifies antitumor immune therapy (Feng et al., 2023). Organic photosensitizers (PS) materials have also shown potential in provoking Pyroptosis and reshaping the TME (Zhou et al., 2018). Oroxylin A (Ori) is another compound that induces Pyroptosis and modulates the TME, demonstrating broad-spectrum anticancer effects (Sun X. et al., 2023).

Insufficient immune cell infiltration in the various TMEs limit the effectiveness of tumor immunotherapy. Radiotherapy, chemotherapy, and targeted therapy can enhance tumor cell immunogenicity, leading to immune cell infiltration and tumor cell demise (Galon and Bruni, 2019; Kroeze et al., 2023; Park et al., 2023). Chemotherapy and radiotherapy-induced acute necroptosis enable DCs to present antigens and activate T cells, resulting in cytotoxic T cell infiltration in the activated TME and tumor eradication. Fucoidan and 5-FU can bolster anticancer immunity by provoking necroptosis and has been widely used and effective in various solid tumors (Zhao et al., 2017; Wang H. et al., 2019). Combination therapy utilizing chemotherapy and immune checkpoint inhibitors (ICI) has shown promising results in cancer treatment and the effects were significantly better than the control group in a randomized, open-label three-phase experiment (Reck et al., 2019). In addition, Polo-like kinase 1 (PLK1) has been identified as a potential inhibitor of tumor immunity and necroptosis. Inhibiting PLK1 may serve as a promising therapeutic strategy (Zhang P. et al., 2023).

In summary, both Pyroptosis and necroptosis play important roles in enhancing tumor immunogenicity and promoting immune cell infiltration in the TME. Strategies involving the induction of Pyroptosis and necroptosis, combinational therapies, and targeting PLK1 hold promise in cancer therapy. It can also trigger deeper thinking for us. Lipid peroxidation induced by oxygen free radicals plays a negative role in the theory of cellular aging. However, in various tumor microenvironments, the induced lipid peroxidation can induce tumor cell programmed death through iron death pathways. This suggests that we can only better utilize the mechanisms of cellular metabolism and survival to benefit the health of all mankind by correctly understanding and further researching them.

4.3 Potential strategies for utilizing ferroptosis as a therapeutic target

Ferroptosis promotes immune cell recruitment and enhances anti-tumor immune response (Chu et al., 2019; Wen et al., 2019). CD8⁺ T cell activation by immune therapy downregulates SLC7A11 expression, inducing cancer cell ferroptosis in patients with melanoma (Wang W. et al., 2019). NRF2 nanomodulators induce ferroptosis in lung cancer cells and stimulate the TME to initiate immune response (Hsieh et al., 2021). Inhibiting MKL-1 expression enhances sensitivity to ferroptosis-inducing agents in TME of gastric cancer (Dai et al., 2023). Chemotherapy drugs and radiotherapy also induce ferroptosis, improving the efficacy of immune checkpoint inhibitor (ICI) immunotherapy by promoting immune cell infiltration and increasing tumor cell immunogenicity (Tong et al., 2022).

Ferroptosis, mediated by lipid peroxidation, aids in tumor antigen recognition and processing by DCs, promoting CD8⁺ T cell presentation and cytotoxic lymphocyte activation, enhancing tumor immunotherapy (Zhao L. et al., 2022). Combining immune checkpoint inhibitors (ICIs) with ferroptosis inducers may increase various tumor cells sensitivity to immune therapy. Several FDA-approved drugs, including glutamine, sorafenib, cisplatin, gemcitabine, and linsitinib, induce ferroptosis and are potential candidates for cancer treatment (Dixon et al., 2014; Stockwell et al., 2017; Guo et al., 2018; Lee et al., 2020; Lv et al., 2020). However, drug resistance is a challenge. Multifunctional ferroptosis nanomedicines have shown promise in effectively reversing treatment resistance (Cai et al., 2024). For example, miR-654-5p enhances sorafenib-induced ferroptosis by targeting HSPB1, improving therapeutic outcomes in Sora-resistant hepatocellular carcinoma (HCC) patients when combined with m654-sEV (Sun J. et al., 2023). Carrier-free nanocomponents containing sorafenib (Sor) and gambogic acid (GA) deplete GSH, inducing ferroptosis in vitro and in vivo, exhibiting potent antitumor activity (Lei et al., 2023). A photoactivated oxygen self-supplying chemical photothermal nanoplatform enhances ferroptosis and alleviates hypoxia-induced chemoresistance in colorectal cancer (CRC) (Jiang et al., 2023). Phenanthroindolizidine alkaloids, natural products that inhibit various cancers, show promise in overcoming tumor resistance (Peng et al., 2023). Combining carbon ion radiotherapy (CIRT) with immunotherapy enhances immune cell infiltration, suggesting a potential role for ferroptosis in synergistic anticancer effects during CIRT combined therapy (Huang Q. et al., 2023).

5 Discussion

5.1 The complexity of cell death

Cell death, particularly ICD and its related forms like inflammation-associated cell pyroptosis, necroptosis, and ferroptosis, plays a key role in cancer development and treatment. These types of cell death stimulate the immune system and trigger crucial anti-tumor responses.

ICD can convert non-immunogenic tumor cells into immunogenic ones, prompting the body’s anti-tumor immune reaction. Released molecules like DAMPs, tumor-associated antigens (TAA), and pro-inflammatory cytokines are captured by DCs and macrophages, initiating antigen-specific immune responses that bolster anti-tumor immunity. Research has found that the inhibition of autophagy can also trigger the accumulation of DAMPs, thereby inducing ICD (Michaud et al., 2011). Clinical use of autophagy inhibition mechanism has shown effective treatment against tumors (Di Lernia et al., 2020). However, further research is needed on the specific pathways and regulatory factors through which autophagy modulation mediates immunogenic cell death. Exploring novel autophagy inhibitors and combination strategies holds promise for improving therapeutic outcomes and represents one of the challenges in the next Frontier of cancer treatment. Similarly, inflammation-associated cell pyroptosis, necroptosis, and ferroptosis exhibit immunogenic properties and can activate the immune system by releasing immune-stimulating substances. And ultimately fostering anti-tumor immune responses (Tang R. et al., 2020).

Yet, the intricate interplay between cell death and the TME cannot be overlooked. The TME is a complex ecosystem comprising tumor cells, immune cells, stromal cells, blood vessels, and others. Cell death not only alters the TME composition but also regulates it. Immune responses induced by ICD can modify the immune landscape of the TME, restraining tumor growth and metastasis. However, considering the TME’s complexity, understanding the molecular mechanisms governing the interaction between cell death and the TME is crucial to optimizing treatment strategies (Kesarwani et al., 2013; Zhou et al., 2016).

5.2 Future direction

Future research should delve deeper into the molecular mechanisms of various forms of cell death, especially key molecules like CRT (Pawaria and Binder, 2011), HMGB1 (van Beijnum et al., 2008), and ATP (Troitskaya et al., 2022) involved in the ICD process. Quantitative and spatial analysis of cell death are also pivotal in refining treatment strategies such as tailoring and monitoring personalized immunotherapy regimens (Banna et al., 2019). Additionally, leveraging advanced technologies and tools like gene editing and nanotechnology to modulate cell death processes presents promising avenues for enhancing cancer treatment efficacy (Li et al., 2017; Dilnawaz and Acharya, 2023).

In essence, the role of cell death in cancer treatment is multifaceted, encompassing the tumor microenvironment, immune responses, and treatment strategies. Future research should focus on delving into these facets and embracing novel technologies and methodologies to tackle the challenges in cancer treatment, ultimately elevating treatment outcomes and patients’ quality of life.

5.3 The detection methods for treating benefit-based patients (such as single-cell analysis)

Through the discussion of various therapeutic approaches inducing programmed cell death and immune cell death, we have discovered that many treatments have strong limitations, benefiting only certain tumor types with specific characteristics, such as patients with myeloproliferative neoplasms carrying CALR mutations showing better outcomes (Fucikova et al., 2021; Huang X. et al., 2023; Chi et al., 2023; Zhao et al., 2023). Therefore, it is crucial to effectively utilize current hot topics like single-cell analysis and other diagnostic tools to classify patients who can or cannot benefit from treatment earlier, faster, and more accurately through cell markers. Many detection models based on single-cell and other technologies have been developed to quickly detect and automatically diagnose various cell types, including but not limited to acute leukemia, breast cancer cell biomarkers, and mature T cells (Zhou et al., 2015; Tsai et al., 2020; Wang et al., 2022).

References

• 1

  AaesT. L.KaczmarekA.DelvaeyeT.De CraeneB.De KokerS.HeyndrickxL.et al (2016). Vaccination with necroptotic cancer cells induces efficient anti-tumor immunity. Cell Rep.15, 274–287. 10.1016/j.celrep.2016.03.037

  • CrossRef
  • Google Scholar

• 2

  AhmedA.TaitS. W. G. (2020). Targeting immunogenic cell death in cancer. Mol. Oncol.14, 2994–3006. 10.1002/1878-0261.12851

  • CrossRef
  • Google Scholar

• 3

  AriaH.RezaeiM. (2023). Immunogenic cell death inducer peptides: a new approach for cancer therapy, current status and future perspectives. Biomed. Pharmacother.161, 114503. 10.1016/j.biopha.2023.114503

  • CrossRef
  • Google Scholar

• 4

  BannaG. L.OlivierT.RundoF.MalapelleU.FraggettaF.LibraM.et al (2019). The promise of digital biopsy for the prediction of tumor molecular features and clinical outcomes associated with immunotherapy. Front. Med. (Lausanne)6, 172. 10.3389/fmed.2019.00172

  • CrossRef
  • Google Scholar

• 5

  BrayF.LaversanneM.WeiderpassE.SoerjomataramI. (2021). The ever-increasing importance of cancer as a leading cause of premature death worldwide. Cancer127, 3029–3030. 10.1002/cncr.33587

  • CrossRef
  • Google Scholar

• 6

  CaiJ.XuX.SawP. E. (2024). Nanomedicine targeting ferroptosis to overcome anticancer therapeutic resistance. Sci. China Life Sci.67, 19–40. 10.1007/s11427-022-2340-4

  • CrossRef
  • Google Scholar

• 7

  Calvillo-RodríguezK. M.Mendoza-RevelesR.Gómez-MoralesL.Uscanga-PalomequeA. C.KaroyanP.Martínez-TorresA. C.et al (2022). PKHB1, a thrombospondin-1 peptide mimic, induces anti-tumor effect through immunogenic cell death induction in breast cancer cells. Oncoimmunology11, 2054305. 10.1080/2162402X.2022.2054305

  • CrossRef
  • Google Scholar

• 8

  ChenX.KangR.KroemerG.TangD. (2021a). Targeting ferroptosis in pancreatic cancer: a double-edged sword. Trends Cancer7, 891–901. 10.1016/j.trecan.2021.04.005

  • CrossRef
  • Google Scholar

• 9

  ChenX.KangR.KroemerG.TangD. (2021b). Broadening horizons: the role of ferroptosis in cancer. Nat. Rev. Clin. Oncol.18, 280–296. 10.1038/s41571-020-00462-0

  • CrossRef
  • Google Scholar

• 10

  ChiH.HuangJ.YanY.JiangC.ZhangS.ChenH.et al (2023). Unraveling the role of disulfidptosis-related LncRNAs in colon cancer: a prognostic indicator for immunotherapy response, chemotherapy sensitivity, and insights into cell death mechanisms. Front. Mol. Biosci.10, 1254232. 10.3389/fmolb.2023.1254232

  • CrossRef
  • Google Scholar

• 11

  ChiH.JiangP.XuK.ZhaoY.SongB.PengG.et al (2022a). A novel anoikis-related gene signature predicts prognosis in patients with head and neck squamous cell carcinoma and reveals immune infiltration. Front. Genet.13, 984273. 10.3389/fgene.2022.984273

  • CrossRef
  • Google Scholar

• 12

  ChiH.PengG.WangR.YangF.XieX.ZhangJ.et al (2022b). Cuprotosis programmed-cell-death-related lncRNA signature predicts prognosis and immune landscape in PAAD patients. Cells11, 3436. 10.3390/cells11213436

  • CrossRef
  • Google Scholar

• 13

  ChuB.KonN.ChenD.LiT.LiuT.JiangL.et al (2019). ALOX12 is required for p53-mediated tumour suppression through a distinct ferroptosis pathway. Nat. Cell Biol.21, 579–591. 10.1038/s41556-019-0305-6

  • CrossRef
  • Google Scholar

• 14

  DaiZ. T.WuY. L.LiX. R.LiaoX. H. (2023). MKL-1 suppresses ferroptosis by activating system Xc- and increasing glutathione synthesis. Int. J. Biol. Sci.19, 4457–4475. 10.7150/ijbs.80666

  • CrossRef
  • Google Scholar

• 15

  DegterevA.HuangZ.BoyceM.LiY.JagtapP.MizushimaN.et al (2005). Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury. Nat. Chem. Biol.1, 112–119. 10.1038/nchembio711

  • CrossRef
  • Google Scholar

• 16

  Di LerniaG.LeoneP.SolimandoA. G.BuonavogliaA.SaltarellaI.RiaR.et al (2020). Bortezomib treatment modulates autophagy in multiple myeloma. J. Clin. Med.9, 552. 10.3390/jcm9020552

  • CrossRef
  • Google Scholar

• 17

  DilnawazF.AcharyaS. (2023). Nanoparticle-based CRISPR/cas delivery: an emerging tactic for cancer therapy. Curr. Med. Chem.30, 3562–3581. 10.2174/0929867329666221006112615

  • CrossRef
  • Google Scholar

• 18

  DixonS. J.LembergK. M.LamprechtM. R.SkoutaR.ZaitsevE. M.GleasonC. E.et al (2012). Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell149, 1060–1072. 10.1016/j.cell.2012.03.042

  • CrossRef
  • Google Scholar

• 19

  DixonS. J.PatelD. N.WelschM.SkoutaR.LeeE. D.HayanoM.et al (2014). Pharmacological inhibition of cystine-glutamate exchange induces endoplasmic reticulum stress and ferroptosis. Elife3, e02523. 10.7554/eLife.02523

  • CrossRef
  • Google Scholar

• 20

  DuQ.WangQ.FanH.WangJ.LiuX.WangH.et al (2016). Dietary cholesterol promotes AOM-induced colorectal cancer through activating the NLRP3 inflammasome. Biochem. Pharmacol.105, 42–54. 10.1016/j.bcp.2016.02.017

  • CrossRef
  • Google Scholar

• 21

  DuanX.ChanC.LinW. (2019). Nanoparticle-mediated immunogenic cell death enables and potentiates cancer immunotherapy. Angew. Chem. Int. Ed. Engl.58, 670–680. 10.1002/anie.201804882

  • CrossRef
  • Google Scholar

• 22

  ElliottM. R.ChekeniF. B.TrampontP. C.LazarowskiE. R.KadlA.WalkS. F.et al (2009). Nucleotides released by apoptotic cells act as a find-me signal to promote phagocytic clearance. Nature461, 282–286. 10.1038/nature08296

  • CrossRef
  • Google Scholar

• 23

  FengZ.ChenG.ZhongM.LinL.MaiZ.TangY.et al (2023). An acid-responsive MOF nanomedicine for augmented anti-tumor immunotherapy via a metal ion interference-mediated pyroptotic pathway. Biomaterials302, 122333. 10.1016/j.biomaterials.2023.122333

  • CrossRef
  • Google Scholar

• 24

  FucikovaJ.SpisekR.KroemerG.GalluzziL. (2021). Calreticulin and cancer. Cell Res.31, 5–16. 10.1038/s41422-020-0383-9

  • CrossRef
  • Google Scholar

• 25

  GalluzziL.KeppO.ChanF. K.KroemerG. (2017). Necroptosis: mechanisms and relevance to disease. Annu. Rev. Pathol.12, 103–130. 10.1146/annurev-pathol-052016-100247

  • CrossRef
  • Google Scholar

• 26

  GalluzziL.VitaleI.WarrenS.AdjemianS.AgostinisP.MartinezA. B.et al (2020). Consensus guidelines for the definition, detection and interpretation of immunogenic cell death. J. Immunother. Cancer8, e000337. 10.1136/jitc-2019-000337

  • CrossRef
  • Google Scholar

• 27

  GalonJ.BruniD. (2019). Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. Nat. Rev. Drug Discov.18, 197–218. 10.1038/s41573-018-0007-y

  • CrossRef
  • Google Scholar

• 28

  GaoW.WangX.ZhouY.WangX.YuY. (2022). Autophagy, ferroptosis, pyroptosis, and necroptosis in tumor immunotherapy. Signal Transduct. Target Ther.7, 196. 10.1038/s41392-022-01046-3

  • CrossRef
  • Google Scholar

• 29

  GlorieuxC.XiaX.HeY. Q.HuY.CremerK.RobertA.et al (2021). Regulation of PD-L1 expression in K-ras-driven cancers through ROS-mediated FGFR1 signaling. Redox Biol.38, 101780. 10.1016/j.redox.2020.101780

  • CrossRef
  • Google Scholar

• 30

  GongY.FanZ.LuoG.YangC.HuangQ.FanK.et al (2019). The role of necroptosis in cancer biology and therapy. Mol. Cancer18, 100. 10.1186/s12943-019-1029-8

  • CrossRef
  • Google Scholar

• 31

  GuoJ.XuB.HanQ.ZhouH.XiaY.GongC.et al (2018). Ferroptosis: a novel anti-tumor action for cisplatin. Cancer Res. Treat.50, 445–460. 10.4143/crt.2016.572

  • CrossRef
  • Google Scholar

• 32

  HabaultJ.KaciA.Pasquereau-KotulaE.FraserC.ChomienneC.DombretH.et al (2020). Prophylactic and therapeutic antileukemic effects induced by the AAC-11-derived Peptide RT53. Oncoimmunology9, 1728871. 10.1080/2162402X.2020.1728871

  • CrossRef
  • Google Scholar

• 33

  HanahanD.WeinbergR. A. (2011). Hallmarks of cancer: the next generation. Cell144, 646–674. 10.1016/j.cell.2011.02.013

  • CrossRef
  • Google Scholar

• 34

  HayesB. H.TsaiR. K.DoolingL. J.KaduS.LeeJ. Y.PantanoD.et al (2020). Macrophages show higher levels of engulfment after disruption of cis interactions between CD47 and the checkpoint receptor SIRPα. J. Cell Sci.133, jcs237800. 10.1242/jcs.237800

  • CrossRef
  • Google Scholar

• 35

  HeR.HuangS.LuJ.SuL.GaoX.ChiH. (2024). Unveiling the immune symphony: decoding colorectal cancer metastasis through immune interactions. Front. Immunol.15, 1362709. 10.3389/fimmu.2024.1362709

  • CrossRef
  • Google Scholar

• 36

  HoS. Y.WuW. J.ChiuH. W.ChenY. A.HoY. S.GuoH. R.et al (2011). Arsenic trioxide and radiation enhance apoptotic effects in HL-60 cells through increased ROS generation and regulation of JNK and p38 MAPK signaling pathways. Chem. Biol. Interact.193, 162–171. 10.1016/j.cbi.2011.06.007

  • CrossRef
  • Google Scholar

• 37

  HollerN.ZaruR.MicheauO.ThomeM.AttingerA.ValituttiS.et al (2000). Fas triggers an alternative, caspase-8-independent cell death pathway using the kinase RIP as effector molecule. Nat. Immunol.1, 489–495. 10.1038/82732

  • CrossRef
  • Google Scholar

• 38

  HouJ.ZhaoR.XiaW.ChangC. W.YouY.HsuJ. M.et al (2020). PD-L1-mediated gasdermin C expression switches apoptosis to pyroptosis in cancer cells and facilitates tumour necrosis. Nat. Cell Biol.22, 1264–1275. 10.1038/s41556-020-0575-z

  • CrossRef
  • Google Scholar

• 39

  HsiehC. H.HsiehH. C.ShihF. S.WangP. W.YangL. X.ShiehD. B.et al (2021). An innovative NRF2 nano-modulator induces lung cancer ferroptosis and elicits an immunostimulatory tumor microenvironment. Theranostics11, 7072–7091. 10.7150/thno.57803

  • CrossRef
  • Google Scholar

• 40

  HsuS. K.LiC. Y.LinI. L.SyueW. J.ChenY. F.ChengK. C.et al (2021). Inflammation-related pyroptosis, a novel programmed cell death pathway, and its crosstalk with immune therapy in cancer treatment. Theranostics11, 8813–8835. 10.7150/thno.62521

  • CrossRef
  • Google Scholar

• 41

  HuangQ.HuJ.ChenL.LinW.YangJ.HuW.et al (2023a). Carbon ion radiotherapy combined with immunotherapy: synergistic anti-tumor efficacy and preliminary investigation of ferroptosis. Cancer Immunol. Immunother.72, 4077–4088. 10.1007/s00262-023-03544-x

  • CrossRef
  • Google Scholar

• 42

  HuangX.ChiH.GouS.GuoX.LiL.PengG.et al (2023b). An aggrephagy-related LncRNA signature for the prognosis of pancreatic adenocarcinoma. Genes (Basel)14, 124. 10.3390/genes14010124

  • CrossRef
  • Google Scholar

• 43

  JiangH.TianH.WangZ.LiB.ChenR.LuoK.et al (2023). Laser-activatable oxygen self-supplying nanoplatform for efficiently overcoming colorectal cancer resistance by enhanced ferroptosis and alleviated hypoxic microenvironment. Biomater. Res.27, 92. 10.1186/s40824-023-00427-1

  • CrossRef
  • Google Scholar

• 44

  JunttilaM. R.de SauvageF. J. (2013). Influence of tumour micro-environment heterogeneity on therapeutic response. Nature501, 346–354. 10.1038/nature12626

  • CrossRef
  • Google Scholar

• 45

  KaczmarekA.VandenabeeleP.KryskoD. V. (2013). Necroptosis: the release of damage-associated molecular patterns and its physiological relevance. Immunity38, 209–223. 10.1016/j.immuni.2013.02.003

  • CrossRef
  • Google Scholar

• 46

  KesarwaniP.MuraliA. K.Al-KhamiA. A.MehrotraS. (2013). Redox regulation of T-cell function: from molecular mechanisms to significance in human health and disease. Antioxid. Redox Signal18, 1497–1534. 10.1089/ars.2011.4073

  • CrossRef
  • Google Scholar

• 47

  KheirandishM.MahboobiH.YazdanparastM.KamalW.KamalM. A. (2018). Anti-cancer effects of metformin: recent evidences for its role in prevention and treatment of cancer. Curr. Drug Metab.19, 793–797. 10.2174/1389200219666180416161846

  • CrossRef
  • Google Scholar

• 48

  KohE.LeeE. J.NamG. H.HongY.ChoE.YangY.et al (2017). Exosome-SIRPα, a CD47 blockade increases cancer cell phagocytosis. Biomaterials121, 121–129. 10.1016/j.biomaterials.2017.01.004

  • CrossRef
  • Google Scholar

• 49

  KongQ.ZhangZ. (2023). Cancer-associated pyroptosis: a new license to kill tumor. Front. Immunol.14, 1082165. 10.3389/fimmu.2023.1082165

  • CrossRef
  • Google Scholar

• 50

  KorenE.FuchsY. (2021). Modes of regulated cell death in cancer. Cancer Discov.11, 245–265. 10.1158/2159-8290.cd-20-0789

  • CrossRef
  • Google Scholar

• 51

  KroemerG.GalassiC.ZitvogelL.GalluzziL. (2022). Immunogenic cell stress and death. Nat. Immunol.23, 487–500. 10.1038/s41590-022-01132-2

  • CrossRef
  • Google Scholar

• 52

  KroezeS. G. C.PavicM.StellamansK.LievensY.BecheriniC.ScorsettiM.et al (2023). Metastases-directed stereotactic body radiotherapy in combination with targeted therapy or immunotherapy: systematic review and consensus recommendations by the EORTC-ESTRO OligoCare consortium. Lancet Oncol.24, e121–e132. 10.1016/s1470-2045(22)00752-5

  • CrossRef
  • Google Scholar

• 53

  KrombachJ.HennelR.BrixN.OrthM.SchoetzU.ErnstA.et al (2019). Priming anti-tumor immunity by radiotherapy: dying tumor cell-derived DAMPs trigger endothelial cell activation and recruitment of myeloid cells. Oncoimmunology8, e1523097. 10.1080/2162402X.2018.1523097

  • CrossRef
  • Google Scholar

• 54

  LeeE.SongC. H.BaeS. J.HaK. T.KarkiR. (2023). Regulated cell death pathways and their roles in homeostasis, infection, inflammation, and tumorigenesis. Exp. Mol. Med.55, 1632–1643. 10.1038/s12276-023-01069-y

  • CrossRef
  • Google Scholar

• 55

  LeeJ.YouJ. H.ShinD.RohJ. L. (2020). Inhibition of glutaredoxin 5 predisposes cisplatin-resistant head and neck cancer cells to ferroptosis. Theranostics10, 7775–7786. 10.7150/thno.46903

  • CrossRef
  • Google Scholar

• 56

  LeeJ. Y.KimW. K.BaeK. H.LeeS. C.LeeE. W. (2021). Lipid metabolism and ferroptosis. Biol. (Basel)10, 184. 10.3390/biology10030184

  • CrossRef
  • Google Scholar

• 57

  LeiJ.ZhangS.WuZ.SunX.ZhouB.HuangP.et al (2023). Self-engineered binary nanoassembly enabling closed-loop glutathione depletion-amplified tumor ferroptosis. Biomater. Sci.11, 7373–7386. 10.1039/d3bm01153d

  • CrossRef
  • Google Scholar

• 58

  LiY.LiuG.MaJ.LinJ.LinH.SuG.et al (2017). Chemotherapeutic drug-photothermal agent co-self-assembling nanoparticles for near-infrared fluorescence and photoacoustic dual-modal imaging-guided chemo-photothermal synergistic therapy. J. Control Release258, 95–107. 10.1016/j.jconrel.2017.05.011

  • CrossRef
  • Google Scholar

• 59

  LiuY.FanD. (2019). Ginsenoside Rg5 induces G2/M phase arrest, apoptosis and autophagy via regulating ROS-mediated MAPK pathways against human gastric cancer. Biochem. Pharmacol.168, 285–304. 10.1016/j.bcp.2019.07.008

  • CrossRef
  • Google Scholar

• 60

  LotzeM. T.DeMarcoR. A. (2003). Dealing with death: HMGB1 as a novel target for cancer therapy. Curr. Opin. Investig. Drugs4, 1405–1409.

  • Google Scholar

• 61

  LvQ.NiuH.YueL.LiuJ.YangL.LiuC.et al (2020). Abnormal ferroptosis in myelodysplastic syndrome. Front. Oncol.10, 1656. 10.3389/fonc.2020.01656

  • CrossRef
  • Google Scholar

• 62

  MichaudM.MartinsI.SukkurwalaA. Q.AdjemianS.MaY.PellegattiP.et al (2011). Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice. Science334, 1573–1577. 10.1126/science.1208347

  • CrossRef
  • Google Scholar

• 63

  MineN.YamamotoS.SaitoN.YamazakiS.SudaC.IshigakiM.et al (2011). CBP501-calmodulin binding contributes to sensitizing tumor cells to cisplatin and bleomycin. Mol. Cancer Ther.10, 1929–1938. 10.1158/1535-7163.MCT-10-1139

  • CrossRef
  • Google Scholar

• 64

  MuppaP.Parrilha TerraS. B. S.SharmaA.MansfieldA. S.AubryM. C.BhingeK.et al (2019). Immune cell infiltration may Be a key determinant of long-term survival in small cell lung cancer. J. Thorac. Oncol.14, 1286–1295. 10.1016/j.jtho.2019.03.028

  • CrossRef
  • Google Scholar

• 65

  NiuX.ChenL.LiY.HuZ.HeF. (2022). Ferroptosis, necroptosis, and pyroptosis in the tumor microenvironment: perspectives for immunotherapy of SCLC. Semin. Cancer Biol.86, 273–285. 10.1016/j.semcancer.2022.03.009

  • CrossRef
  • Google Scholar

• 66

  OzbenT. (2007). Oxidative stress and apoptosis: impact on cancer therapy. J. Pharm. Sci.96, 2181–2196. 10.1002/jps.20874

  • CrossRef
  • Google Scholar

• 67

  PaixãoE.OliveiraA. C. M.PizatoN.Muniz-JunqueiraM. I.MagalhãesK. G.NakanoE. Y.et al (2017). The effects of EPA and DHA enriched fish oil on nutritional and immunological markers of treatment naïve breast cancer patients: a randomized double-blind controlled trial. Nutr. J.16, 71. 10.1186/s12937-017-0295-9

  • CrossRef
  • Google Scholar

• 68

  ParkH. H.KimH. R.ParkS. Y.HwangS. M.HongS. M.ParkS.et al (2021). RIPK3 activation induces TRIM28 derepression in cancer cells and enhances the anti-tumor microenvironment. Mol. Cancer20, 107. 10.1186/s12943-021-01399-3

  • CrossRef
  • Google Scholar

• 69

  ParkJ.NahY.KimW. J. (2023). Ido-triggered swellable polymeric micelles for Ido inhibition and targeted cancer immunotherapy. J. Control Release363, 496–506. 10.1016/j.jconrel.2023.09.050

  • CrossRef
  • Google Scholar

• 70

  Pasquereau-KotulaE.HabaultJ.KroemerG.PoyetJ. L. (2018). The anticancer peptide RT53 induces immunogenic cell death. PLoS One13, e0201220. 10.1371/journal.pone.0201220

  • CrossRef
  • Google Scholar

• 71

  PawariaS.BinderR. J. (2011). CD91-dependent programming of T-helper cell responses following heat shock protein immunization. Nat. Commun.2, 521. 10.1038/ncomms1524

  • CrossRef
  • Google Scholar

• 72

  PengR.XuM.XieB.MinQ.HuiS.DuZ.et al (2023). Insights on antitumor activity and mechanism of natural benzophenanthridine alkaloids. Molecules28, 6588. 10.3390/molecules28186588

  • CrossRef
  • Google Scholar

• 73

  ReckM.MokT. S. K.NishioM.JotteR. M.CappuzzoF.OrlandiF.et al (2019). Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial. Lancet Respir. Med.7, 387–401. 10.1016/S2213-2600(19)30084-0

  • CrossRef
  • Google Scholar

• 74

  RobertsonC. A.EvansD. H.AbrahamseH. (2009). Photodynamic therapy (PDT): a short review on cellular mechanisms and cancer research applications for PDT. J. Photochem Photobiol. B96, 1–8. 10.1016/j.jphotobiol.2009.04.001

  • CrossRef
  • Google Scholar

• 75

  SeoJ.NamY. W.KimS.OhD. B.SongJ. (2021). Necroptosis molecular mechanisms: recent findings regarding novel necroptosis regulators. Exp. Mol. Med.53, 1007–1017. 10.1038/s12276-021-00634-7

  • CrossRef
  • Google Scholar

• 76

  ShenY.ChiH.XuK.LiY.YinX.ChenS.et al (2022). A novel classification model for lower-grade glioma patients based on pyroptosis-related genes. Brain Sci.12, 700. 10.3390/brainsci12060700

  • CrossRef
  • Google Scholar

• 77

  SnyderA. G.HubbardN. W.MessmerM. N.KofmanS. B.HaganC. E.OrozcoS. L.et al (2019). Intratumoral activation of the necroptotic pathway components RIPK1 and RIPK3 potentiates antitumor immunity. Sci. Immunol.4, eaaw2004. 10.1126/sciimmunol.aaw2004

  • CrossRef
  • Google Scholar

• 78

  SongB.WuP.LiangZ.WangJ.ZhengY.WangY.et al (2022). A novel necroptosis-related gene signature in skin cutaneous melanoma prognosis and tumor microenvironment. Front. Genet.13, 917007. 10.3389/fgene.2022.917007

  • CrossRef
  • Google Scholar

• 79

  StockwellB. R.Friedmann AngeliJ. P.BayirH.BushA. I.ConradM.DixonS. J.et al (2017). Ferroptosis: a regulated cell death nexus linking metabolism, redox biology, and disease. Cell171, 273–285. 10.1016/j.cell.2017.09.021

  • CrossRef
  • Google Scholar

• 80

  SunJ.LiuQ.JiangY.CaiZ.LiuH.ZuoH. (2023b). Engineered small extracellular vesicles loaded with miR-654-5p promote ferroptosis by targeting HSPB1 to alleviate sorafenib resistance in hepatocellular carcinoma. Cell Death Discov.9, 362. 10.1038/s41420-023-01660-2

  • CrossRef
  • Google Scholar

• 81

  SunX.LiM.WangP.BaiQ.CaoX.MaoD. (2023a). Recent organic photosensitizer designs for evoking proinflammatory regulated cell death in antitumor immunotherapy. Small Methods7, e2201614. 10.1002/smtd.202201614

  • CrossRef
  • Google Scholar

• 82

  TangD.KeppO.KroemerG. (2020b). Ferroptosis becomes immunogenic: implications for anticancer treatments. Oncoimmunology10, 1862949. 10.1080/2162402X.2020.1862949

  • CrossRef
  • Google Scholar

• 83

  TangR.XuJ.ZhangB.LiuJ.LiangC.HuaJ.et al (2020a). Ferroptosis, necroptosis, and pyroptosis in anticancer immunity. J. Hematol. Oncol.13, 110. 10.1186/s13045-020-00946-7

  • CrossRef
  • Google Scholar

• 84

  TemkinV.HuangQ.LiuH.OsadaH.PopeR. M. (2006). Inhibition of ADP/ATP exchange in receptor-interacting protein-mediated necrosis. Mol. Cell Biol.26, 2215–2225. 10.1128/MCB.26.6.2215-2225.2006

  • CrossRef
  • Google Scholar

• 85

  TongX.TangR.XiaoM.XuJ.WangW.ZhangB.et al (2022). Targeting cell death pathways for cancer therapy: recent developments in necroptosis, pyroptosis, ferroptosis, and cuproptosis research. J. Hematol. Oncol.15, 174. 10.1186/s13045-022-01392-3

  • CrossRef
  • Google Scholar

• 86

  TroitskayaO.VarlamovM.NushtaevaA.RichterV.KovalO. (2020). Recombinant lactaptin induces immunogenic cell death and creates an antitumor vaccination effect in vivo with enhancement by an ido inhibitor. Molecules25, 2804. 10.3390/molecules25122804

  • CrossRef
  • Google Scholar

• 87

  TroitskayaO. S.NovakD. D.RichterV. A.KovalO. A. (2022). Immunogenic cell death in cancer therapy. Acta Naturae14, 40–53. 10.32607/actanaturae.11523

  • CrossRef
  • Google Scholar

• 88

  TsaiA. G.GlassD. R.JuntillaM.HartmannF. J.OakJ. S.Fernandez-PolS.et al (2020). Multiplexed single-cell morphometry for hematopathology diagnostics. Nat. Med.26, 408–417. 10.1038/s41591-020-0783-x

  • CrossRef
  • Google Scholar

• 89

  Uscanga-PalomequeA. C.Calvillo-RodríguezK. M.Gómez-MoralesL.LardéE.DenèfleT.Caballero-HernándezD.et al (2019). CD47 agonist peptide PKHB1 induces immunogenic cell death in T-cell acute lymphoblastic leukemia cells. Cancer Sci.110, 256–268. 10.1111/cas.13885

  • CrossRef
  • Google Scholar

• 90

  van BeijnumJ. R.BuurmanW. A.GriffioenA. W. (2008). Convergence and amplification of toll-like receptor (TLR) and receptor for advanced glycation end products (RAGE) signaling pathways via high mobility group B1 (HMGB1). Angiogenesis11, 91–99. 10.1007/s10456-008-9093-5

  • CrossRef
  • Google Scholar

• 91

  WangC.WangC.WuY.GaoJ.HanY.ChuY.et al (2022). High-throughput, living single-cell, multiple secreted biomarker profiling using microfluidic chip and machine learning for tumor cell classification. Adv. Healthc. Mater11, e2102800. 10.1002/adhm.202102800

  • CrossRef
  • Google Scholar

• 92

  WangH.TangY.FangY.ZhangM.WangH.HeZ.et al (2019a). Reprogramming tumor immune microenvironment (TIME) and metabolism via biomimetic targeting codelivery of shikonin/JQ1. Nano Lett.19, 2935–2944. 10.1021/acs.nanolett.9b00021

  • CrossRef
  • Google Scholar

• 93

  WangT.HuJ.LuoH.LiH.ZhouJ.ZhouL.et al (2018). Photosensitizer and autophagy promoter coloaded ROS-responsive dendrimer-assembled carrier for synergistic enhancement of tumor growth suppression. Small14, e1802337. 10.1002/smll.201802337

  • CrossRef
  • Google Scholar

• 94

  WangW.GreenM.ChoiJ. E.GijónM.KennedyP. D.JohnsonJ. K.et al (2019b). CD8(+) T cells regulate tumour ferroptosis during cancer immunotherapy. Nature569, 270–274. 10.1038/s41586-019-1170-y

  • CrossRef
  • Google Scholar

• 95

  WangY.ShenW.LiuS.ZhuG.MengX.MaoK.et al (2021). The host-defense-peptide-mimicking synthetic polypeptides effectively enhance antitumor immunity through promoting immunogenic tumor cell death. Macromol. Biosci.21, e2100171. 10.1002/mabi.202100171

  • CrossRef
  • Google Scholar

• 96

  WeinlichR.OberstA.BeereH. M.GreenD. R. (2017). Necroptosis in development, inflammation and disease. Nat. Rev. Mol. Cell Biol.18, 127–136. 10.1038/nrm.2016.149

  • CrossRef
  • Google Scholar

• 97

  WenQ.LiuJ.KangR.ZhouB.TangD. (2019). The release and activity of HMGB1 in ferroptosis. Biochem. Biophys. Res. Commun.510, 278–283. 10.1016/j.bbrc.2019.01.090

  • CrossRef
  • Google Scholar

• 98

  WenY.ZhangW.GongN.WangY. F.GuoH. B.GuoW.et al (2017). Carrier-free, self-assembled pure drug nanorods composed of 10-hydroxycamptothecin and chlorin e6 for combinatorial chemo-photodynamic antitumor therapy in vivo. Nanoscale9, 14347–14356. 10.1039/c7nr03129g

  • CrossRef
  • Google Scholar

• 99

  XieD.WangQ.WuG. (2022). Research progress in inducing immunogenic cell death of tumor cells. Front. Immunol.13, 1017400. 10.3389/fimmu.2022.1017400

  • CrossRef
  • Google Scholar

• 100

  XieY.ZhuS.ZhongM.YangM.SunX.LiuJ.et al (2017). Inhibition of aurora kinase A induces necroptosis in pancreatic carcinoma. Gastroenterology153, 1429–1443. 10.1053/j.gastro.2017.07.036

  • CrossRef
  • Google Scholar

• 101

  XuH.ZhangD.WeiR.ZhouY.DaiG.LiJ.et al (2022). Gambogic acid induces pyroptosis of colorectal cancer cells through the GSDME-dependent pathway and elicits an antitumor immune response. Cancers (Basel)14, 5505. 10.3390/cancers14225505

  • CrossRef
  • Google Scholar

• 102

  YangW. S.SriRamaratnamR.WelschM. E.ShimadaK.SkoutaR.ViswanathanV. S.et al (2014). Regulation of ferroptotic cancer cell death by GPX4. Cell156, 317–331. 10.1016/j.cell.2013.12.010

  • CrossRef
  • Google Scholar

• 103

  YangY.ZhuT.WangX.XiongF.HuZ.QiaoX.et al (2022). ACSL3 and ACSL4, distinct roles in ferroptosis and cancers. Cancers (Basel)14, 5896. 10.3390/cancers14235896

  • CrossRef
  • Google Scholar

• 104

  YuH.GuoP.XieX.WangY.ChenG. (2017). Ferroptosis, a new form of cell death, and its relationships with tumourous diseases. J. Cell Mol. Med.21, 648–657. 10.1111/jcmm.13008

  • CrossRef
  • Google Scholar

• 105

  ZhangP.ZhangX.ZhuY.CuiY.XuJ.ZhangW. (2023b). Polo-like kinase 1 suppresses lung adenocarcinoma immunity through necroptosis. Oncol. Res.31, 937–953. 10.32604/or.2023.030933

  • CrossRef
  • Google Scholar

• 106

  ZhangR.XingR.JiaoT.MaK.ChenC.MaG.et al (2016). Carrier-free, chemophotodynamic dual nanodrugs via self-assembly for synergistic antitumor therapy. ACS Appl. Mater Interfaces8, 13262–13269. 10.1021/acsami.6b02416

  • CrossRef
  • Google Scholar

• 107

  ZhangR. N.JingZ. Q.ZhangL.SunZ. J. (2023a). Epigenetic regulation of pyroptosis in cancer: molecular pathogenesis and targeting strategies. Cancer Lett.575, 216413. 10.1016/j.canlet.2023.216413

  • CrossRef
  • Google Scholar

• 108

  ZhaoD.ZhangH.TaoW.WeiW.SunJ.HeZ. (2017). A rapid albumin-binding 5-fluorouracil prodrug with a prolonged circulation time and enhanced antitumor activity. Biomater. Sci.5, 502–510. 10.1039/c6bm00884d

  • CrossRef
  • Google Scholar

• 109

  ZhaoL.ZhouX.XieF.ZhangL.YanH.HuangJ.et al (2022b). Ferroptosis in cancer and cancer immunotherapy. Cancer Commun. (Lond)42, 88–116. 10.1002/cac2.12250

  • CrossRef
  • Google Scholar

• 110

  ZhaoL. P.ZhengR. R.ChenH. Q.LiuL. S.ZhaoX. Y.LiuH. H.et al (2020). Self-delivery nanomedicine for O(2)-economized photodynamic tumor therapy. Nano Lett.20, 2062–2071. 10.1021/acs.nanolett.0c00047

  • CrossRef
  • Google Scholar

• 111

  ZhaoS.ChiH.JiW.HeQ.LaiG.PengG.et al (2022a). A bioinformatics-based analysis of an anoikis-related gene signature predicts the prognosis of patients with low-grade gliomas. Brain Sci.12, 1349. 10.3390/brainsci12101349

  • CrossRef
  • Google Scholar

• 112

  ZhaoS.ZhangX.GaoF.ChiH.ZhangJ.XiaZ.et al (2023). Identification of copper metabolism-related subtypes and establishment of the prognostic model in ovarian cancer. Front. Endocrinol. (Lausanne)14, 1145797. 10.3389/fendo.2023.1145797

  • CrossRef
  • Google Scholar

• 113

  ZhengD.LiuJ.XieL.WangY.DingY.PengR.et al (2022). Enzyme-instructed and mitochondria-targeting peptide self-assembly to efficiently induce immunogenic cell death. Acta Pharm. Sin. B12, 2740–2750. 10.1016/j.apsb.2021.07.005

  • CrossRef
  • Google Scholar

• 114

  ZhouB.LiuJ.KangR.KlionskyD. J.KroemerG.TangD. (2020). Ferroptosis is a type of autophagy-dependent cell death. Semin. Cancer Biol.66, 89–100. 10.1016/j.semcancer.2019.03.002

  • CrossRef
  • Google Scholar

• 115

  ZhouH.ForveilleS.SauvatA.YamazakiT.SenovillaL.MaY.et al (2016). The oncolytic peptide LTX-315 triggers immunogenic cell death. Cell Death Dis.7, e2134. 10.1038/cddis.2016.47

  • CrossRef
  • Google Scholar

• 116

  ZhouL.WangH.YiJ.YangB.LiM.HeD.et al (2018). Anti-tumor properties of anthocyanins from Lonicera caerulea 'Beilei' fruit on human hepatocellular carcinoma: in vitro and in vivo study. Biomed. Pharmacother.104, 520–529. 10.1016/j.biopha.2018.05.057

  • CrossRef
  • Google Scholar

• 117

  ZhouL.WangR.YaoC.LiX.WangC.ZhangX.et al (2015). Single-band upconversion nanoprobes for multiplexed simultaneous in situ molecular mapping of cancer biomarkers. Nat. Commun.6, 6938. 10.1038/ncomms7938

  • CrossRef
  • Google Scholar

• 118

  ZhuX.LiS. (2023). Ferroptosis, necroptosis, and pyroptosis in gastrointestinal cancers: the chief culprits of tumor progression and drug resistance. Adv. Sci. (Weinh)10, e2300824. 10.1002/advs.202300824

  • CrossRef
  • Google Scholar